跳至主要内容
临床试验/CTRI/2023/09/057446
CTRI/2023/09/057446尚未招募3 期

Further Axillary Treatment vs No Treatment in cT1-3N1M0 Breast Cancer Patients with Node Negativity after Neoadjuvant Chemotherapy: A Randomized Controlled Trial - Nil

Dr Brijesh Kumar Singh0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Age = 18 years
  • 3.Disease stage: cT1-3N1M0 at diagnosis (prior to NACT) as per AJCC 8th edition
  • 4.Patients with confirmed metastasis on FNA or core biopsy in the axillary node at presentation
  • 5.Estrogen receptor and HER2 status evaluated on primary tumour
  • 6.Received standard NACT as per local guidelines
  • 7.Axilla imaging to assess response to NACT (as per local guidelines)
  • 8.Undergo dual tracer sentinel node biopsy (SNB) after NACT and at least 3 nodes removed in total (sentinel nodes and marked node).
  • ?If a single tracer is used, the patient will be eligible if the involved node is marked before or during NACT, and the marked node and at least 3 nodes (including the marked node) are removed during sentinel node biopsy.
  • ?If axillary node sampling is performed following failed localization of sentinel nodes, the patient will be eligible if at least 3 nodes are removed (including the marked node).
  • ?If node is not marked, or marked node is not removed, the patient will be eligible if the histology report shows evidence of down-staging with complete pathological response e.g., fibrosis or scarring in at least one node and at least 3 nodes removed.
  • ?If fewer than 3 nodes are found on histology, the patient is eligible if: a) involved node was marked and removed during SNB; and b) removed marked node shows evidence of downstaging on histology e.g., fibrosis or scarring.
  • No evidence of nodal metastases posts NACT (isolated tumour cells, micro or macro metastasis)

排除标准

  • 1.Bilateral synchronous invasive breast cancer
  • 2.Sentinel node biopsy prior to NACT
  • 3.Previous axillary nodal surgery on the same body side as the scheduled targeted sampling
  • 4.Any previous cancer within last 5 years or concomitant malignancy except contra- or ipsilateral in situ breast cancer

研究者

发起方
Dr Brijesh Kumar Singh

相似试验